Richard B. Bankert VMD, PhD

Richard Bankert

Richard B. Bankert
VMD, PhD

Professor of Microbiology

Department of Microbiology and Immunology

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Immunology

Contact Information
217 Biomedical Research Building
Buffalo, NY 14214
Phone: (716) 829-2701
rbankert@buffalo.edu



Professional Summary:

My research focus is on the study of the interaction of inflammatory leukocytes and fibroblasts with tumor cells in human lung and ovarian tumor microenvironments by using an immunodeficient tumor xenograft model. This model includes the tumor, the tumor-associated stromal fibroblasts and the inflammatory cells, including lymphocytes.

In my lab, I work with a research team of students and postdoctoral fellows to study the immune response of cancer patients to their tumors. Our data indicate that tumor-specific lymphocytes, once present in the tumor microenvironment, become hyporesponsive and fail to attack and kill tumor cells. This hyporesponsiveness is due to an arrest or checkpoint in the T cell receptor (TCR) signaling machinery. Our studies are designed to gain a better understanding of the molecular events that are responsible for signaling arrest. We also aim to determine ways to prevent, or even reverse the TCR signaling arrest, for example, by eliminating or blocking the lipid-mediated disruption of the TCR signaling cascade.

Using the tumor xenograft models, we have structurally identified the immunoinhibitory factors present within the tumor ascites fluids and determined the mechanism by which they arrest the TCR signaling. We found that these cells fail to respond to activation signals due to the disruption of the TCR signaling cascade that occurs at, or just proximal to the activation of PLC-γ. An identical TCR signaling arrest also occurs in human T cells found in chronic inflammatory tissues. Using the xenograft models, we established that a local and sustained release of IL-12 into the tumor microenvironment activates the quiescent tumor-associated T cells to produce and secrete IFN-γ, which mobilizes an immune-mediated eradication of the tumor.

We recently found that lipids present within the ascites fluids of human ovarian tumor mediate a reversible arrest in the TCR signaling pathway of ovarian tumor-associated T cells. We have now determined that extracellular microvesicles (exosomes) isolated from human ovarian tumors and tumor ascites induce a rapid and reversible arrest in the T cell signaling cascade. The T cell inhibition is causally linked to phosphatidylserine that is expressed on the outer leaflet of the exosome membrane. The target of this arrest is diacylglycerol, and the induced suppression is blocked or reversed by diacylglycerol kinase inhibitors. This suggests a likely mechanism by which the tumor-associated exosomes arrest both CD4+ and CD8+ T cell activation.

The ability to eliminate or block/reverse that inhibitory activity of the exosomes represents a potentially viable therapeutic target for enhancing patients’ antitumor response and for preventing the loss of function of CAR-T cells upon entry into the tumor microenviroment.

These findings will provide valuable information in designing new immunotherapeutic strategies for patients with advanced cancer.

Education and Training:

  • PhD, Immunology, University of Pennsylvania (1973)
  • VMD, Vet. Medicine, University of Pennsylvania (1968)
  • BA, Chem. & Biol., Gettysburg College (1962)

Employment:

  • Professor, Microbiology and Immunology, State University of New York at Buffalo (2001-present)
  • Professor, Immunology, Roswell Park Div. of the State University of New York at Buffalo (1991-present)
  • Associate Chief Cancer Research Scientist VI, Roswell Park Cancer Institute (1982–1996)
  • Associate Professor, Immunology, Roswell Park Div of State University of New York at Buffalo (1988–1991)
  • Cancer Research Scientist V, Molecular Immunology, Roswell Park Cancer Institute (1978–1983)
  • Cancer Research Scientist IV, Molecular Immunology, Roswell Park Cancer Institute (1977–1978)
  • Cancer Research Scientist III, Molecular Immunology, Roswell Park Cancer Institute (1976–1977)
  • Cancer Research Scientist II, Molecular Immunology, Roswell Park Cancer Institute (1973–1976)
  • Postdoctoral Research Fellow in Immunology, Dept. Pathobiology, University of Pennsylvania (1970–1973)
  • Postdoctoral Research Fellow, University of Pennsylvania, School of Veterinary Medicine (1968–1970)

Awards and Honors:

  • Chancellor's Award for Excellence (2013)

Research Expertise:

  • Immunobiology: Human t-cell regulation by lipids
  • Tumor immunology: Immunotherapy, Human tumor cell microenvironment, Tumor xenograpfts in mice asa surrogate approach to cancer therapy

Grants and Sponsored Research:

  • February 2002–December 2019
    Development and pharmacology of novel lipidic rAHF and Biotherapeutics
    NHLBI
    Role: Co-Investigator
    $1,000,000
  • December 2007–November 2018
    Re-activating memory T cells in the microenvironment of human tumors
    NCI
    Role: Principal Investigator
    $217,764
  • July 2004–January 2015
    CD4+ memory T-cells in human tumor microenvironment
    NCI
    Role: Principal Investigator
    $198,947
  • July 2005–June 2006
    Product Development Fund
    University at Buffalo
    Role: Co-Investigator
    $33,000
  • January 2001–January 2006
    VHIg Peptide Vaccine Strategies for B-Cell Lymphomas
    NIH
    Role: Principal Investigator
    $150,000
  • January 2000–January 2004
    VHIg Peptide Vaccines for Human B-Cell Malignancies
    NIH
    Role: Principal Investigator
    $224,784
  • January 2000–December 2002
    A Tumor VH Peptide Vaccine for Patients with Non-Hodgkins Lymphoma
    NIH
    Role: Co-Investigator
    $100,000
  • January 1997–December 2002
    Immunity and Immunotherapy of Human Cancer in SCID Mice
    NIH
    Role: Principal Investigator
    $95,750
  • January 1991–December 2002
    Factors Affecting Human Lung Tumor Growth in SCID Mice
    NIH
    Role: Principal Investigator
    $194,866
  • January 2000–January 2002
    Bioadhesive Microspheres for Colon Cancer Therapy
    NIH
    Role: Co-Principal Investigator
    $194,000
See all (1 more)

Patents:

  • method of preparation of liposomes Composition and method of preparation of liposomal microparticulate IL-12 for immunotherapy (2010)
  • Preparation of Liposomes Compositions and methods of preparation of liposomal microparticulate IL-12. (2006)
  • Immunoassays and fractionation Microflotation devices used for immunoassays and cell/molecular fractionation (1991)
  • Cells and their use Coated Cells and Their Use (1985)

Journal Articles:

  • Singel KL, Emmons TR, Khan ANH, Mayor PC, Shen S, Wong JT, Morrell K, Eng KH, Mark J, Bankert RB, Matsuzaki J, Koya RC, Blom AM, McLeish KR, Qu J, Ram S, Moysich KB, Abrams SI, Odunsi K, Zsiros E, Segal BH. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight. 2019; 4(5).
  • Shenoy GN, Loyall J, Berenson CS, Kelleher RJ, Iyer V, Balu-Iyer SV, Odunsi K, Bankert RB. Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. J Immunol. 2018; 201(12).
  • Glassman FY, Schneider JL, Ramakrishnan R, Dingman RK, Ramanathan M, Bankert RB, Balu-Iyer SV. Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher. J Pharm Sci. 2018; 107(8).
  • Shenoy GN, Loyall J, Maguire O, Iyer V, Kelleher RJ, Minderman H, Wallace PK, Odunsi K, Balu-Iyer SV, Bankert RB. Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunol Res. 2018; 6(2).
  • Burack WR, Spence JM, Spence JP, Spence SA, Rock PJ, Shenoy GN, Shultz LD, Bankert RB, Bernstein SH. Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment. Blood Adv. 2017; 1(16).
  • Kelleher RJ, Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, Iyer V, Fathallah AM, Berenson CS, Wallace PK, Tario J, Odunsi K, Bankert RB. Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. Cancer Immunol Res. 2015; 3(11).
  • Fathallah AM, Bankert RB, Balu-Iyer SV. Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective. AAPS J. 2013; 15(4).
  • Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ, Odunsi K, Bankert RB. Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells. Cancer Immun. 2013; 13.
  • Gaitonde P, Ramakrishnan R, Chin J, Kelleher RJ, Bankert RB, Balu-Iyer SV. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice. J Biol Chem. 2013; 288(24).
  • Yokota SJ, Facciponte JG, Kelleher RJ, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB. Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun. 2013; 13.
See all (135 more)

Books and Book Chapters:

  • Egilmez, N.K., Jong, Y.S., Mathiowitz, E., Richard Bankert. Tumor vaccination with cytokine-encapsulated microspheres. Methods in Molecular Medicine. 2001.
  • Mazzaferro, P.K., Richard Bankert. Biochemistry of immunoglobulins. The Clinical Chemistry of Laboratory Animals. 1999.
  • Richard Bankert, Umemoto, T., Sugiyama, Y., Chen, F.A., Repasky, E., Yokota, S.. Human lung tumors, patients' peripheral blood lymphocytes and tumor infiltrating lymphocytes propagated in SCID mice. proc. of the EMBO Workshop on the SCID Mouse, Basell, Switzerland, Feb. 1989. Curr. Topics In Microbiol. and Immunol.. 1989; 152.
  • Lou, S-C., Richard Bankert. Use of congenic and recombinant inbred mouse strains to link a highly conserved idiotypic marker to an Igh-C region allotype locus and to map this new member of the Q52 gene family within the Igh-V gene complex. H-2 Antigens, Genes and Molecules, Function. 1988; 144.
  • Richard Bankert, Abbas, A.K.. Myelomas as models to study activation and suppression of normal lymphocytes. Progress in Myelomas. 1980.


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

217 Biomedical Research Building
Buffalo, NY 14214
Phone: (716) 829-2701
rbankert@buffalo.edu